Log in

NASDAQ:HOOKHookipa Pharma Stock Price, Forecast & News

$10.30
0.00 (0.00 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.73
Now: $10.30
$10.48
50-Day Range
$9.34
MA: $11.14
$12.10
52-Week Range
$5.80
Now: $10.30
$14.37
Volume37,177 shs
Average Volume77,436 shs
Market Capitalization$224.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HOOK
CUSIPN/A
CIKN/A
Phone431-890-6360

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.94 million
Book Value$5.46 per share

Profitability

Net Income$-43,040,000.00
Net Margins-333.02%

Miscellaneous

Employees56
Market Cap$224.80 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive HOOK News and Ratings via Email

Sign-up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.

Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions

How has Hookipa Pharma's stock been impacted by COVID-19 (Coronavirus)?

Hookipa Pharma's stock was trading at $9.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HOOK shares have increased by 11.4% and is now trading at $10.30. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hookipa Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hookipa Pharma.

When is Hookipa Pharma's next earnings date?

Hookipa Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Hookipa Pharma.

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.01. The company earned $3.70 million during the quarter, compared to analysts' expectations of $4.36 million. Hookipa Pharma had a negative net margin of 333.02% and a negative return on equity of 36.53%. View Hookipa Pharma's earnings history.

What price target have analysts set for HOOK?

2 Wall Street analysts have issued 1 year target prices for Hookipa Pharma's stock. Their forecasts range from $15.00 to $23.00. On average, they anticipate Hookipa Pharma's stock price to reach $19.00 in the next year. This suggests a possible upside of 84.5% from the stock's current price. View analysts' price targets for Hookipa Pharma.

Has Hookipa Pharma been receiving favorable news coverage?

Headlines about HOOK stock have been trending negative this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hookipa Pharma earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Hookipa Pharma.

Are investors shorting Hookipa Pharma?

Hookipa Pharma saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 723,700 shares, an increase of 300.5% from the May 31st total of 180,700 shares. Based on an average trading volume of 78,700 shares, the days-to-cover ratio is currently 9.2 days. Approximately 6.2% of the shares of the company are short sold. View Hookipa Pharma's Current Options Chain.

Who are some of Hookipa Pharma's key competitors?

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Atreca (BCEL), Homology Medicines (FIXX), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Stoke Therapeutics (STOK), Akero Therapeutics (AKRO) and Tcr2 Therapeutics (TCRR).

Who are Hookipa Pharma's key executives?

Hookipa Pharma's management team includes the following people:
  • Mr. Joern Aldag, Pres, CEO & Director (Age 60)
  • Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)
  • Dr. Reinhard Kandera, CFO & Director (Age 50)
  • Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)
  • Mrs. Nina Waibel, Communications & Investor Relations Mang.

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

How do I buy shares of Hookipa Pharma?

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $10.30.

How big of a company is Hookipa Pharma?

Hookipa Pharma has a market capitalization of $224.80 million and generates $11.94 million in revenue each year. The company earns $-43,040,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Hookipa Pharma employs 56 workers across the globe.

What is Hookipa Pharma's official website?

The official website for Hookipa Pharma is www.hookipapharma.com.

How can I contact Hookipa Pharma?

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.